Roche?s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
- Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
- Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency
- Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December